Evidence-Based Strategies for Psychiatric Nurse Practitioners
| Strategy | Response Rate | Notes |
|---|---|---|
| Combination Antidepressants | 45% | SSRI + Mirtazapine superior |
| Aripiprazole Augmentation | 44% | FDA approved, VAST-D trial |
| Quetiapine Augmentation | 42% | Sedating, metabolic monitoring |
| Lithium Augmentation | 40% | Target 0.6-0.8 mmol/L |
| Switching (Monotherapy) | 19% | Less effective than augmentation |
| Drug | CYP2D6 | CYP3A4 | Risk |
|---|---|---|---|
| Paroxetine | Strong | Weak | High (3-4x antipsychotic levels) |
| Fluoxetine | Strong | Moderate | High (long half-life) |
| Bupropion | Strong | Negligible | Moderate/High |
| Fluvoxamine | Weak | Strong | High (unique profile) |
| Escitalopram | Negligible | Negligible | Low (safest for polypharmacy) |
High Risk: SSRIs + Tramadol/Fentanyl | MAOIs + Serotonergics | Multiple antidepressants + Triptans
Diagnosis requires ONE of (84% sensitivity, 97% specificity):
Treatment: Stop serotonergics, supportive care, cyproheptadine 8mg q8h for severe cases.
| Medication | Taper Schedule |
|---|---|
| SSRI/SNRI | 10% reductions every 2-4 weeks (hyperbolic) |
| Benzodiazepines | 25% reductions every 1-2 weeks |
| Antipsychotics | 10-25% reductions every 2-4 weeks |
Hyperbolic tapering: Follows receptor occupancy curves, not linear dosing. Slower at lower doses.